AI Article Synopsis
- XEN gel stents are designed for treating open-angle glaucoma (OAG) when other treatments have failed, with a focus on evaluating their impact on intraocular pressure (IOP), medication needs, and safety.
- A systematic review of 56 relevant studies involving 4,410 eyes showed that the stents significantly reduced IOP by about 35% and decreased the need for antiglaucoma medications.
- The treatment demonstrated a good safety profile, with less than 1% incidence of serious complications, while achieving a complete success rate of 21.0-70.8% over two years.
Article Abstract
Purpose: XEN gel stents are used for the treatment of open-angle glaucoma (OAG), including primary and secondary glaucoma that are uncontrolled by previous medical therapy and cases with previous failed surgery. Our aim was to systematically review of the clinical data of currently published ab-interno XEN gel stents with an emphasis on intraocular pressure (IOP), antiglaucoma medication outcomes, and safety profiles.
Methods: We analyzed all of the publications (MEDLINE, EMBASE, Cochrane Library) on the ab-interno XEN gel stent to evaluate the reduction in IOP and antiglaucoma medications following the procedure. The primary outcomes measured for the meta-analysis were reduction in IOP and anti-glaucoma medications. The secondary outcome were adverse events. For each study, we used a random effects analysis model to calculate the mean difference and 95% confidence intervals for the continuous results (reduction in IOP and antiglaucoma medications) using the inverse variance statistical method.
Results: Five hundred twenty-seven articles were checked and 56 studies were found to be relevant with a total of 4,410 eyes. There was a significant reduction in IOP as well as in the number of medications required in patients treated with ab-interno XEN implant either alone or combined with cataract surgery. This new treatment for various types of glaucoma reduced the IOP by 35% to a final average close to 15 mmHg. This reduction was accompanied by a decrease in the number of antiglaucoma medications in all the studies, approximately 2 classes of medication at the price of more needlings. The overall complete success rate was 21.0-70.8% after 2 years using strict criteria originally designed to record success rate in filtration surgery. The incidence of complications vision-threatening was low at <1%.
Conclusions: XEN gel stent was effective and safe for primary and secondary OAG. Further studies should be performed to investigate the impact of ethnicity on the success and failure rate after XEN implantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854748 | PMC |
| http://dx.doi.org/10.3389/fmed.2022.804847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing XEN microstent's one-year efficacy: independent of site variability.
Int J Ophthalmol
January 2025
Department of Ophthalmology, University of Leipzig, Liebigstrasse 10-14, Leipzig 04103, Germany.
Aim: To evaluate the short-term efficacy of XEN45 Gel Stent (XEN) implantation for primary open angle glaucoma (POAG) and pseudoexfoliation (PEX) glaucoma across two university eye clinics, aiming to assess the impact of varying center-specific protocols during the first postoperative year.
Methods: We retrospectively examined 282 patients (183 in center 1, 99 in center 2), who underwent XEN microstent implantation for uncontrolled POAG or PEX glaucoma. Parameters including intraocular pressure (IOP), IOP-lowering medication count, best corrected visual acuity (BCVA), and postoperative complications were evaluated over 12mo.
Macaroni necklace technique - Removal of a Xen gel stent.
Am J Ophthalmol Case Rep
December 2024
Casey Eye Institute at Oregon Health and Science University, 515 SW Campus Dr., Portland, OR, 97239, USA.
This video demonstrates the novel "macaroni necklace" technique for removing a Xen gel stent. The technique allows for complete removal of the stent without the hydrated and soft pieces from tearing apart. In this case, the stent was the nidus for endophthalmitis, and complete removal is necessary for prevention of future infections.
View Article and Find Full Text PDFClinical outcomes of Xen 45 gel stent implantation(Ab externo, open conjunctival approach) versus Trabeculectomy: A real world study.
Korean J Ophthalmol
December 2024
Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, South Korea.
Article Synopsis
- The study compared clinical outcomes of Xen 45 gel stent surgery and trabeculectomy in glaucoma patients, analyzing data from 62 eyes treated with Xen and 78 eyes with trabeculectomy over specific periods.
- Results showed a lower complete success rate for Xen (33.9%) compared to trabeculectomy (57.7%), along with higher postoperative intraocular pressure and more glaucoma medications needed in the Xen group; however, it had fewer complications (0% vs. 16.7%) and shorter operation time.
- Both surgical methods yielded similar postoperative best corrected visual acuity but differed in success rates, medication requirements, and safety profiles, indicating that while Xen may be quicker and safer
Transconjunctival XEN® 45 Gel Stent Implantation: Efficacy and Safety of a New Surgical Technique.
J Curr Glaucoma Pract
October 2024
Department of Ophthalmology, Hospital of San Severino Marche, AV3- Asur Marche, Macerata, Italy.
Article Synopsis
- This study aimed to assess the effectiveness and safety of a new surgical method called transconjunctival XEN® 45 gel stent implantation in treating primary open-angle glaucoma (POAG).
- A total of 31 patients underwent the procedure, experiencing an average decrease in intraocular pressure from 25.3 mm Hg pre-surgery to 15.9 mm Hg post-surgery, with most not needing additional medications by the one-month follow-up.
- The results suggest that this surgical technique is both safe and effective, offering a timely alternative for patients with POAG needing surgical intervention earlier in their treatment process.
Three-Year Results of XEN-45 Implantation for Glaucoma Secondary to Fuchs Uveitis Syndrome, Intermediate Uveitis, and Juvenile Idiopathic Arthritis-Related Anterior Uveitis.
Ocul Immunol Inflamm
November 2024
Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany.
Purpose: To investigate the long-term outcomes of XEN-45 implantation for glaucoma secondary to Fuchs uveitis syndrome (FUS), juvenile idiopathic arthritis (JIA)-related anterior uveitis and intermediate uveitis (IU).
Methods: This retrospective study evaluated 19 eyes with FUS, 10 eyes with JIA, and nine eyes with IU that underwent XEN-45 Gel Stent implantation. The primary outcome measure was 3-year surgical success, defined as a ≥20% reduction in intraocular pressure (IOP), with a target IOP of 6-21 mmHg.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!